Restrictions for patents owners to preserve the public interest in the sufficient availability of necessary medicinal products
GDPR and life sciences – part 2
The Bolar and related exemptions in Europe
What activity do they cover?
par plusieurs auteurs
Falsified Medicine Directive continued: Safety features on medicinal products and its consequences
GDPR and private sector life sciences
par Debbie Heywood et Sally Annereau
National perspectives on the CJEU Bayer decision
par plusieurs auteurs
Global Data Hub - life sciences
par plusieurs auteurs
Infringement of second medical use patents in the UK: pregabalin in the Supreme Court
Synapse - December 2019
par plusieurs auteurs
First Dutch GDPR fine for failing to ensure security of patient files